Among nine subgroups defined according to primary tumour location and RAS-, and BRAF-V600E status, metastasectomy rates were the lowest among patients with BRAF-V600Emt right colon tumours (12%) and the highest among patients with RAS&BRAFwt rectal tumours (42%; Fig. 1A). This evidence concerns the gene BRAF and colonic neoplasm.